| 貨號 | 規格 | 價格 | 上海 | 北京 | 武漢 | 南京 | 購買數量 |
|---|---|---|---|---|---|---|---|
S83244-1mg |
99.0% | ￥319.60 | 6 | - | - | - |
|
S83244-2mg |
99.0% | ￥408.00 | 7 | - | - | - |
|
S83244-5mg |
99.0% | ￥584.80 | 7 | - | - | - |
|
S83244-10mg |
99.0% | ￥1020.00 | 7 | - | - | - |
|
S83244-25mg |
99.0% | ￥2380.00 | 5 | - | - | - |
|
S83244-50mg |
≥98% | ￥4080.00 | 貨期：2-3天 | - | - | - |
|
S83244-100mg |
≥98% | ￥6664.00 | 貨期：2-3天 | - | - | - |
|
ML-18 is a non-peptide bombesin receptor subtype-3 (BRS-3) antagonist with an IC50 of 4.8 μM.
| 產品描述： | ML-18 is a non-peptide bombesin receptor subtype-3 (BRS-3) antagonist with an IC50 of 4.8 μM. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶點： | IC50: 4.8 μM (BRS-3);BombesinReceptor | ||||||||||||||||||||
| 體外研究： | ML-18 inhibits specific 125I-BA1 (DTyr-Gln-Trp-Ala-Val-βAla-His-Phe-Nle-NH2)BB6-14 binding to NCI-H1299 lung cancer cells stably transfected with BRS-3 with IC50 values of 4.8 μM. ML-18 binds with lower affinity to the GRPR and NMBR with IC50 values of 16 and more than 100 μM, respectively. ML-18 at 16 μM inhibits the ability of 10 nM BA1 to elevate cytosolic Ca2+ in a reversible manner using lung cancer cells loaded with FURA2-AM. ML-18 at 16 μM inhibits the ability of 100 nM BA1 to cause tyrosine phosphorylation of the EGFR and ERK in lung cancer cells. It inhibits the proliferation of lung cancer cells | ||||||||||||||||||||
| 參考文獻： | 1. Moody TW, et al. ML-18 is a non-peptide bombesin receptor subtype-3 antagonist which inhibits lung cancer growth. Peptides. 2015 Feb;64:55-61. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存條件： | -20℃ | ||||||||||||||||||||
| 配置溶液濃度參考： |
|
||||||||||||||||||||
| 注意： | 部分產品我司僅能提供部分信息，我司不保證所提供信息的權威性，僅供客戶參考交流研究之用。 |
上海工商
滬公網安備 31011702002021號
危險品化學品經營許可證（不帶存儲）
營業執照(三證合一)
北京